



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

| | |
|---------------|--|
| Last Trade: | 0.92 |
| Trade Time: | 4:00 PM ET Jun 23, 2017 |
| Change: | -0.08 ↓ (-7.576%) |
| Day Range | 0.90 - 1.04 |
| 52-Week Range | 0.90 - 5.35 |
| Volume | 4,554,369 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*SM biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Jun 13, 2017
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer](#)
- [Jun 12, 2017
Regulus Announces Pipeline Updates and Advancements](#)
- [Jun 1, 2017
Pascale Witz Joins Regulus Board of Directors](#)
- [May 4, 2017
Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring](#)
- [Apr 27, 2017
Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- [Mar 3, 2017
Annual Report \(10-K\)](#)
- [Apr 28, 2017
Proxy Statement \(DEF 14A\)](#)
- [May 5, 2017
Quarterly Report \(10-Q\)](#)
- [Nov 2, 2016
Quarterly Report \(10-Q\)](#)
- [Aug 3, 2016
Quarterly Report \(10-Q\)](#)